BiotechTube

15mg DU-176b + 30mg DU-176b + Fondaparinux

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Venous Thromboembolism

Conditions

Venous Thromboembolism

Trial Timeline

Mar 1, 2012 → Dec 1, 2012

NCT ID
NCT01857583

About 15mg DU-176b + 30mg DU-176b + Fondaparinux

15mg DU-176b + 30mg DU-176b + Fondaparinux is a phase 3 stage product being developed by Daiichi Sankyo for Venous Thromboembolism. The current trial status is completed. This product is registered under clinical trial identifier NCT01857583. Target conditions include Venous Thromboembolism.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01857583Phase 3Completed

Competing Products

20 competing products in Venous Thromboembolism

See all competitors
ProductCompanyStageHype Score
EdoxabanDaiichi SankyoPre-clinical
23
DU-176b 15mg + DU-176b 30mg + Enoxaparin sodium 20 mg (=2000IU)Daiichi SankyoPhase 2
52
Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3
77
EdoxabanDaiichi SankyoPre-clinical
23
Edoxaban + Standard of CareDaiichi SankyoPhase 3
77
DU-176b + DU-176b + DU-176b + DU-176b + PlaceboDaiichi SankyoPhase 2
52
DU-176b (edoxaban) + Enoxaparin sodium 20mgDaiichi SankyoPhase 3
77
edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
77
edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarinDaiichi SankyoPhase 3
77
YM150Astellas PharmaPhase 3
77
YM150Astellas PharmaPhase 3
77
YM150 + enoxaparinAstellas PharmaPhase 2/3
65
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
65
YM150Astellas PharmaPhase 3
77
YM150Astellas PharmaPhase 3
77
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
65
Dalteparin sodium + Dalteparin sodium/aspirinEisaiPre-clinical
23
dalteparin injectionEisaiPhase 3
77
ONO-7684 + ONO-7684 PlaceboOno PharmaceuticalPhase 1
33
Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + (LMW) Heparin + Vitamin K AntagonistJohnson & JohnsonPhase 2
52

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85